129 related articles for article (PubMed ID: 20719856)
21. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
[TBL] [Abstract][Full Text] [Related]
22. Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs.
Sato A; Hara Y
Res Vet Sci; 2018 Aug; 119():61-66. PubMed ID: 29864631
[TBL] [Abstract][Full Text] [Related]
23. Human kallikrein 10 expression in surgically removed human pituitary corticotroph adenomas: an immunohistochemical study.
Di Meo A; Rotondo F; Kovacs K; Cusimano MD; Syro LV; Di Ieva A; Diamandis EP; Yousef GM
Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):433-7. PubMed ID: 25517869
[TBL] [Abstract][Full Text] [Related]
24. Cushing's disease due to double pituitary ACTH-secreting adenomas: the first case report.
Andrioli M; Pecori Giraldi F; Losa M; Terreni M; Invitti C; Cavagnini F
Endocr J; 2010; 57(9):833-7. PubMed ID: 20595779
[TBL] [Abstract][Full Text] [Related]
25. Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomas.
Cassarino MF; Sesta A; Pagliardini L; Losa M; Lasio G; Cavagnini F; Pecori Giraldi F
Endocrine; 2017 Mar; 55(3):853-860. PubMed ID: 27220856
[TBL] [Abstract][Full Text] [Related]
26. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas.
Morris DG; Kola B; Borboli N; Kaltsas GA; Gueorguiev M; McNicol AM; Ferrier R; Jones TH; Baldeweg S; Powell M; Czirják S; Hanzély Z; Johansson JO; Korbonits M; Grossman AB
J Clin Endocrinol Metab; 2003 Dec; 88(12):6080-7. PubMed ID: 14671214
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of trichostatin A on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT-20 cells.
Nakada Y; Kageyama K; Sugiyama A; Desaki R; Takayasu S; Niioka K; Murasawa S; Ishigame N; Asari Y; Iwasaki Y; Daimon M
Endocr J; 2015; 62(12):1083-90. PubMed ID: 26497760
[TBL] [Abstract][Full Text] [Related]
28. AT-101 acts as anti-proliferative and hormone suppressive agent in mouse pituitary corticotroph tumor cells.
Yurekli BS; Karaca B; Kisim A; Bozkurt E; Atmaca H; Cetinkalp S; Ozgen G; Yilmaz C; Uzunoglu S; Uslu R; Saygili F
J Endocrinol Invest; 2018 Feb; 41(2):233-240. PubMed ID: 28730425
[TBL] [Abstract][Full Text] [Related]
29. Expression of Neuropeptide Y and Its Relationship with Molecular and Morphological Changes in Human Pituitary Adenomas.
Jia R; Li M; Chang B; Chen L; Ma J
Cancer Biother Radiopharm; 2015 Dec; 30(10):411-9. PubMed ID: 26683132
[TBL] [Abstract][Full Text] [Related]
30. Expression of neuro D1 in human normal pituitaries and pituitary adenomas.
Oyama K; Sanno N; Teramoto A; Osamura RY
Mod Pathol; 2001 Sep; 14(9):892-9. PubMed ID: 11557786
[TBL] [Abstract][Full Text] [Related]
31. Bone morphogenetic protein 4 and bone morphogenetic protein receptor expression in the pituitary gland of adult dogs in healthy condition and with ACTH-secreting pituitary adenoma.
Sato A; Ochi H; Harada Y; Yogo T; Kanno N; Hara Y
Domest Anim Endocrinol; 2017 Jan; 58():126-133. PubMed ID: 26542941
[TBL] [Abstract][Full Text] [Related]
32. Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.
Ruebel KH; Leontovich AA; Jin L; Stilling GA; Zhang H; Qian X; Nakamura N; Scheithauer BW; Kovacs K; Lloyd RV
Endocrine; 2006 Jun; 29(3):435-44. PubMed ID: 16943582
[TBL] [Abstract][Full Text] [Related]
33. Liver X receptor-α/β expression ratio is increased in ACTH-secreting pituitary adenomas.
Hashimoto K; Matsumoto S; Ishida E; Miura A; Horiguchi K; Ozawa A; Shibusawa N; Satoh T; Yamada M; Yamada S; Mori M
Neurosci Lett; 2011 Apr; 494(1):34-7. PubMed ID: 21356276
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
35. HDAC2 expression and variable number of repeats in exon 1 of the HDAC2 gene in corticotroph adenomas.
Evang JA; Borota OC; Melum E; Holm R; Ramm-Pettersen J; Bollerslev J; Berg JP
Clin Endocrinol (Oxf); 2010 Aug; 73(2):229-35. PubMed ID: 20346000
[TBL] [Abstract][Full Text] [Related]
36. Molecular Biology of Pituitary Adenomas.
Faltermeier CM; Magill ST; Blevins LS; Aghi MK
Neurosurg Clin N Am; 2019 Oct; 30(4):391-400. PubMed ID: 31471046
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in understanding corticotroph pituitary tumor initiation and progression.
Renner U; Ciato D; Stalla GK
F1000Res; 2018; 7():. PubMed ID: 30228864
[TBL] [Abstract][Full Text] [Related]
38. Orbital invasion by ACTH-secreting pituitary adenomas.
Dhaliwal JS; Seibold LK; Kleinschmidt-Demasters BK; Lillehei KO; Hink EM; Prall JA; Durairaj VD
Ophthalmic Plast Reconstr Surg; 2014; 30(2):e28-30. PubMed ID: 23645353
[TBL] [Abstract][Full Text] [Related]
39. Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.
Grzywa TM; Klicka K; Rak B; Mehlich D; Garbicz F; Zieliński G; Maksymowicz M; Sajjad E; Włodarski PK
Endocrine; 2019 Sep; 65(3):646-655. PubMed ID: 31165412
[TBL] [Abstract][Full Text] [Related]
40. Decreased expression of SFRP2 promotes development of the pituitary corticotroph adenoma by upregulating Wnt signaling.
Ren J; Jian F; Jiang H; Sun Y; Pan S; Gu C; Chen X; Wang W; Ning G; Bian L; Sun Q
Int J Oncol; 2018 Jun; 52(6):1934-1946. PubMed ID: 29620167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
